At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 47 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome
In Brief
A Phase 3 clinical trial evaluating Placebo and Memantine for Ischemic Stroke and 2 related conditions. Completed, enrolled 47 participants.
Detailed Summary
The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Excitotoxicity, Memantine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartOct 2015
Primary CompletionOct 2016
Study CompletionSep 2017
TodayJul 2026
First PostedAug 28, 2015
Enrollment StartOct 1, 2015
Primary CompletionOct 1, 2016
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.8 years ago
Interventions
Placebodrug
Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Memantinedrug
Beside the usual treatment for ischemic stroke this group will be treated by memantine.